Yadanzigan

Research use only, not for human use.

Yadanzigan (YDZG) is an anti-inflammatory agent and a NLRP3 inhibitor. Yadanzigan specifically inhibits NLRP3 activation via inhibiting NF-κB pathway and Reactive Oxygen Species production. Yadanzigan also moderates LPS -induced acute lung injury (ALI) in mice.

Yadanzigan (YDZG) is an anti-inflammatory agent and a NLRP3 inhibitor. Yadanzigan specifically inhibits NLRP3 activation via inhibiting NF-κB pathway and Reactive Oxygen Species production. Yadanzigan also moderates LPS -induced acute lung injury (ALI) in mice.

Western Blot AnalysisCell Line:J774A.1, and THP-1 cells Concentration:For J774A.1: 2.5 μM, 5 μM, and 10 μM; For THP-1: 10 μM, 20 μM, and 40 μM Incubation Time:For J774A.1: 6 h, 12 h; For THP-1: 1 hour; 2 h before 1 μg/mL LPS stimulated and another 30 min before 5 mM ATP induced Result:Led to a sharp decrease in NLRP3 expression in J774A.1 cells.Led to a large decrease in NLRP3 protein expression in a dose-dependent manner in THP-1 cells.Immunofluorescence Cell Line:RAW264.7 macrophages, THP-1 cells Concentration:20, 40, and 80 μM Incubation Time:Pre-treated for 1 h, continue to incubate for 18 h Result:Decreased caspase-1 p20 activation and mature IL-1β and inhibited cleaved caspase-1 release into supernatants.

Animal Model:Male BABL/C mice (18-22 g) Dosage:5 mg/kg, 10 mg/kg Administration:Intravenous injection; dose at 2 h prior to and 6 h, 12 h after LPS induction Result:Reduced LPS-induced infiltration of inflammatory cells and cytokine levels, such as TNF-α and IL-6. Inhibited NLRP3 inflammasome activation in lung tissue.Resulted significantly greater survival rate.

———

Others

Other Targets

NLRP3 inflammasome

———

———

76588-87-9

574.6

C26H38O14

>98% (HPLC)

———

———

——

(-20℃)

With Ice Pack

≥ 2 years